Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We expect the fundamentals of the eye care market to remain strong, and we expect each of our segments to deliver growth in 2024 |
| And so, again, great outcomes, great patient and satisfaction |
| Double-digit growth is always impressive, but even more so when you consider how we got there |
| Our quality of growth is what helps set us apart from others, and that will be enhanced as we've entered one of the most active launch years in our company's history |
| So, pretty excited about the consumer business, combined with just a great team, right? We have a really strong team at B+L on consumer |
| We're making solid progress in both areas |
| And so, really healthy performance there |
| We have demonstrated great growth in the consumer business, up 11% |
| What gets me really excited as I think about 2024 and beyond, and I hope as we continue to interact with all of you in 2024, you'll see a strong focus on execution and driving this company to reach its potential in the years to come |
| And I think our performance was very strong |
| And their experience with Miebo with patients has been excellent, right? And the reason that is you look at refill rates, which are trending way above dry eye category refill rates |
| 12% constant currency revenue growth would earn the highest grade on its own, but again, I'm more impressed with how we did it |
| So, really positive momentum there |
| That's our fastest-growing product and a great contact lens |
| And so, to summarize, I'd say we have two of our businesses in really good shape, and two that are focused on execution and delivery |
| Incremental improvements will be reflected in margin expansion, and long-term success will be foundational for a future-proof Bausch + Lomb |
| So, the setup there is really nice for constant new product, new innovation and higher margin products to drive through that business |
| In fact, I only see opportunity as both vision care and surgical in particular felt the effects of operational challenges, some self-inflicted, others out of our control, yet both delivered impressive year-over-year growth |
| And I think the team did a really good job, and the excitement among that community was strong and remains strong |
| Now, Medicare has the longest lead time or lag time to drive coverage, but I'm optimistic we'll do a strong performance in 2024 |
| That actually is the way you run a surgical business, and it has a tremendous benefit of driving margin improvement |
| 2026, we're going to have nice margin improvement |
| In the fourth quarter, we once again saw strong revenue growth across each of our segments and key product franchises |
| We're pleased with how we ended the year and our performance for the full year in 2023 |
| Our business demonstrated growth in revenue and adjusted EBITDA, with revenue exceeding our full-year guidance |
| We have - on the hunt for other things to add to the bag, but we have a lot of strength and a lot of growth for several years to come in pharma, and lots of opportunities to add innovation |
| We're growing faster than the market |
| I'll be discussing the impact of these key dry eye franchises more throughout the call, but the headline is that we're highly encouraged by what we're seeing so far |
| Touching briefly on supply, we have continued to make improvements to strengthen our supply chain in 2023, and we're pleased with the progress |
| While there's still work to be done, we feel confident about the path forward |
| Statement |
|---|
| Revenue in the lens portfolio was negatively impacted throughout 2023 by disruptions at our Lynchburg distribution facility |
| This was balanced by pressure on the gross margin driven by the higher inventory costs in our surgical business |
| Full year 2023 adjusted EBITDA was negatively impacted by currency headwinds of $51 million, and Lynchburg-related disruptions of $30 million |
| But I think IC-8, I think from memory, you guys still have some production challenges there |
| Based on current exchange rates, we estimate currency headwinds to have a negative impact on revenue of approximately $40 million for the full year |
| For the full year, currency was a headwind of $68 million to revenue and $51 million to adjusted EBITDA |
| Hasty climbers have sudden falls as the saying goes, which means we won't lose sight of our long-term goals for short-term gains |
| As I mentioned last quarter, our standard EyeCee One IOL continues to be impacted by the product recall issued by our partner in 2023, which offset the strong growth in our premium IOL portfolio |
| Post-launch excitement hasn't waned |
| Despite an average growth of more than 25% among the key franchises highlighted, they haven't realized their full potential, not by a long shot |
| When you think about our guidance for 2024, we're covering a significant amount of headwind |
| The full year 2023 adjusted tax rate was 4%, which is slightly lower than our previous guidance of approximately 6% |
| We've continued to see currency headwinds moderate |
| So, if you think about 2024 for us, we'll follow a similar trend as we saw in 2023, with our first quarter being the lowest in terms of contribution and fourth quarters is the highest |
| The issue there is, right, driving production capability, and that is in place, but it will take a few quarters to get to where we want to get to |
| While they appear to have the lowest mark, a single check mark, it's really more of an incomplete or too new to rate |
| Demand is also a theme in dry eye, as we've made clear, and while the focus is often on prescription medications, we’ve built a formidable stable of OTC dry eye brands on a global scale, most notably Artelac |
| Not ready to call the number yet, but I did put in some optimism |
| Our third-party manufacturing there is struggling |
| The first quarter, because of deductibles, is always the weakest, and the fourth quarter is always the strongest |
Please consider a small donation if you think this website provides you with relevant information